New study shows UroAmp can detect bladder cancer not found by cystoscopy or urine cytology 

Noninvasive Genomic Urine Test Demonstrates High Accuracy in Predicting Recurrence Before Clinical Signs or Symptoms Emerge

SOUTH SAN FRANCISCO, Calif.Aug. 22, 2023 /PRNewswire/ — UroAmp, the noninvasive genomic urine test developed by Convergent Genomics, can detect bladder cancer or predict its recurrence before clinical signs or symptoms appear, according to a newly published study in the journal Clinical Cancer Research

read more